The FDA Has Approved Haemonetics' Advancements To Its NexSys PCS Plasma Collection System, Including A New Plasma Collection Bowl And New Express Plus Technology Engineered To Reduce Procedure Time
Portfolio Pulse from Benzinga Newsdesk
The FDA has approved Haemonetics' advancements to its NexSys PCS Plasma Collection System, including a new plasma collection bowl and new Express Plus technology engineered to reduce procedure time.
June 22, 2023 | 10:17 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Haemonetics Corporation (HAE) received FDA approval for advancements to its NexSys PCS Plasma Collection System, including a new plasma collection bowl and Express Plus technology to reduce procedure time.
The FDA approval of Haemonetics' advancements to its NexSys PCS Plasma Collection System is a positive development for the company. The new plasma collection bowl and Express Plus technology will likely improve the efficiency of the system, potentially leading to increased demand and sales. This could have a positive impact on HAE's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100